vaccin
consider
impact
societi
elimin
threat
sever
infecti
diseas
although
vaccin
gener
proven
safe
safeti
issu
arisen
result
member
public
poor
percept
vaccin
howev
technolog
advanc
made
recent
year
make
develop
even
safer
vaccin
possibl
new
gener
vaccin
base
pure
recombin
protein
conjug
kill
virus
addit
studi
conduct
larg
number
individu
allay
unjustifi
fear
vaccin
safeti
data
increas
public
confid
ensur
vaccin
becom
better
appreci
valuabl
product
widespread
confid
inspir
effect
commun
realiti
benefittorisk
ratio
vaccin
see
front
matter
elsevi
ltd
right
reserv
pii
w
introduct
vaccin
medic
practic
begin
last
centuri
extraordinari
impact
human
health
repres
unparallel
success
stori
modern
medicin
vaccin
broadli
consid
safest
effect
medic
intervent
strategi
conjunct
introduct
antibiot
modern
hygien
vaccin
significantli
contribut
steadi
declin
mortal
morbid
caus
infecti
diseas
tabl
vaccin
respons
erad
viru
caus
smallpox
signific
effort
underway
erad
polioviru
erad
natur
occur
smallpox
also
result
elimin
need
continu
vaccin
ultim
success
vaccin
howev
termin
vaccin
open
possibl
deliber
reintroduct
pathogen
bioterror
recent
review
highlight
valu
vaccin
also
emphas
vaccin
often
underus
undervalu
year
pediatr
vaccin
prevent
three
million
death
worldwid
protect
children
seriou
disabl
nevertheless
issu
vaccin
safeti
us
sinc
vaccin
first
establish
centuri
figur
continu
attract
intens
scrutini
although
pediatr
vaccin
use
safe
decad
rel
recent
shift
public
percept
safeti
result
vaccin
polici
incid
sever
vaccineprevent
diseas
western
societi
low
exampl
diphtheria
tetanu
tabl
encourag
parent
suggest
children
longer
need
vaccin
howev
approach
ignor
societ
respons
fail
appreci
crucial
role
herd
immun
prevent
circul
pathogen
protect
whole
popul
vaccin
effect
alway
suscept
popul
prone
advers
consequ
infect
includ
immunocompromis
individu
peopl
genet
suscept
moreov
infecti
diseas
disproportion
affect
young
old
infirm
peopl
often
impair
immun
popul
suscept
peopl
increas
health
care
improv
extend
life
expect
peopl
suffer
chronic
diseas
vaccin
often
mandatori
ensur
protect
individu
might
choos
vaccin
safeti
vaccin
describ
real
safeti
problem
highlight
addit
safeti
issu
wide
public
without
support
evid
discuss
immun
polici
usa
predominantli
determin
advisor
committe
immun
practic
acip
http
wwwcdcgovnipacip
advisori
group
us
public
health
servic
center
diseas
control
prevent
cdc
http
wwwcdcgov
infant
vaccin
accord
current
guidelin
receiv
separ
inject
protect
differ
infecti
diseas
time
two
year
age
although
recommend
western
societi
differ
polici
usa
broadli
repres
industri
societi
given
number
inject
requir
close
tempor
relationship
vaccin
onset
mani
childhood
diseas
surpris
consider
specul
link
onset
diseas
childhood
vaccin
tabl
even
though
valu
vaccin
clear
tabl
nevertheless
detail
studi
undertaken
possibl
caus
link
vaccin
mostli
elimin
proven
includ
claim
link
hepat
b
vaccin
multipl
sclerosi
ms
mani
approach
current
evalu
facilit
vaccin
without
use
needl
includ
mucos
deliveri
vaccin
technolog
devic
topic
immun
howev
none
strategi
yet
close
establish
routin
use
although
claim
complet
safeti
imposs
medic
intervent
almost
year
accumul
evid
involv
mani
billion
dose
state
confid
vaccin
enviabl
exemplari
safeti
profil
howev
vaccin
shown
caus
safeti
problem
minor
individu
tabl
vaccin
administ
annual
hundr
million
infant
therefor
level
scrutini
continu
intens
consequ
safeti
hurdl
approv
new
vaccin
high
rigor
detail
evalu
routin
vaccin
shown
safeti
problem
tabl
import
lesson
learn
approach
modifi
avoid
repeat
problem
although
seriou
advers
event
rare
occurr
power
impact
affect
individu
closest
henc
even
rare
advers
event
neg
impact
vaccin
broadli
report
put
context
rel
occurr
versu
benefit
afford
vaccin
prevent
support
vaccin
polici
public
health
agenc
industri
academia
respons
journalist
role
play
ensur
benefit
vaccin
explain
acknowledg
advers
event
occur
although
articl
focu
princip
develop
world
global
perspect
world
health
organ
http
wwwwhoint
safeti
vaccin
recent
discuss
review
technolog
improv
safeti
vaccin
administr
report
first
intern
symposium
vaccin
safeti
also
recent
publish
recent
exampl
use
highlight
vaccin
safeti
illustr
vaccin
commun
respond
appar
problem
market
product
live
oral
rotaviru
vaccin
introduc
onto
market
immun
infant
year
later
product
withdrawn
associ
intussuscept
rare
seriou
obstruct
intestin
licensur
five
case
intussuscept
report
vaccin
recipi
versu
one
case
placebo
recipi
howev
nine
month
licensur
cdc
recommend
vaccin
suspend
exist
data
evalu
investig
relationship
vaccin
intussuscept
subsequ
epidemiolog
studi
appear
confirm
excess
case
intussuscept
administr
first
dose
recommend
use
vaccin
withdrawn
acip
henc
argu
postlicensur
surveil
usa
effect
identifi
safeti
problem
appear
low
level
moreov
safeti
databas
requir
allow
licensur
subsequ
rotaviru
vaccin
expand
studi
underway
infant
secondgener
product
stori
rotaviru
vaccin
usa
bring
import
issu
relat
safeti
andor
benefit
analysi
vaccin
remov
list
recommend
vaccin
low
level
incid
potenti
seriou
advers
event
rotaviru
infect
normal
fatal
usa
contrast
rotaviru
caus
death
per
annum
develop
world
although
administr
rotaviru
vaccin
could
prevent
mani
death
recommend
withdrawn
usa
consid
uneth
promot
vaccin
develop
world
despit
fact
would
save
mani
live
fortun
secondgener
rotaviru
vaccin
move
late
stage
develop
test
includ
safeti
evalu
larg
number
infant
moreov
appear
origin
vaccin
might
ddt
vol
oral
polio
viru
revers
virul
live
vaccin
requir
larger
stabl
delet
approv
live
oral
rotaviru
intussuscept
vaccin
longer
recommend
requir
safeti
databas
expand
futur
product
inactiv
measl
atyp
measl
vaccin
remov
market
intranas
flu
bacteri
bell
palsi
facial
paralysi
vaccin
remov
market
toxin
adjuv
wholecel
pertussi
vaccin
reactogen
remov
market
major
develop
world
anthrax
cellfre
filtrat
product
anthrax
vaccin
adsorb
purifi
recombin
protein
avail
near
futur
swine
flu
syndrom
vaccin
discontinu
reintroduc
onto
market
http
follow
reevalu
exist
safeti
data
long
develop
molecular
method
enabl
specif
engin
recombin
virus
live
attenu
oral
polioviru
vaccin
opv
develop
use
empir
method
involv
passag
viru
cell
cultur
howev
shortli
introduct
opv
sporad
case
vaccineassoci
paralyt
polio
report
level
one
per
recipi
rare
situat
attenu
mutat
present
one
vaccin
strain
could
potenti
caus
live
opv
revert
virul
nevertheless
opv
vaccin
continu
use
worldwid
could
respons
erad
polio
infect
next
year
howev
level
polio
fall
opv
gradual
replac
altern
kill
inactiv
polio
vaccin
ipv
caus
polio
even
suscept
individu
import
lesson
futur
live
vaccin
accept
unless
clear
understand
molecular
attenu
potenti
revers
virul
elimin
either
result
size
number
attenu
delet
molecular
biolog
techniqu
made
possibl
prevent
live
virus
revert
virul
histori
develop
ipv
also
taught
vaccin
commun
second
import
lesson
long
introduct
ipv
clinic
use
discov
earli
ipv
contamin
simian
viru
cell
line
use
produc
vaccin
although
oncogen
sever
speci
extens
investig
shown
use
contamin
ipv
result
increas
rate
cancer
vaccin
recipi
nevertheless
result
problem
rule
regul
control
use
cellcultur
system
vaccin
extens
improv
continu
evolv
today
meet
addit
challeng
includ
need
use
media
reagent
anim
proven
free
transmiss
spongiform
enceph
tse
vaccin
whoop
cough
first
develop
formalin
inactiv
bacteri
cell
later
combin
tetanu
diphtheria
toxoid
creat
first
combin
vaccin
although
wholecel
vaccin
effect
protect
whoop
cough
concern
advers
reaction
began
accumul
particularli
regard
seizur
infantil
spasm
public
opinion
turn
wholecel
vaccin
use
declin
predict
result
upsurg
incid
diseas
mortal
whoop
cough
final
establish
extrem
case
wholecel
pertussi
vaccin
could
caus
acut
transient
fever
hypotonichyporespons
episod
inconsol
cri
seizur
evid
vaccin
caus
chronic
neurolog
problem
howev
neg
public
poor
accept
wholecel
vaccin
result
extens
research
identifi
protect
antigen
pertussi
earli
sever
compani
includ
glaxosmithklin
http
wwwgskcom
aventi
pasteur
http
wwwaventispasteurcom
wyeth
lederl
http
chiron
vaccin
http
wwwchironcom
initi
program
evalu
potenc
subunit
vaccin
could
combin
tetanu
diphtheria
vaccin
develop
subunit
pertussi
vaccin
consid
start
minimalist
approach
vaccin
develop
necessari
antigen
includ
vaccin
sever
product
shown
effect
protect
diseas
replac
wholecel
vaccin
develop
world
howev
increas
cost
subunit
pertussi
vaccin
yet
avail
develop
world
predominantli
consequ
success
vaccin
morbid
mortal
associ
mani
acut
childhood
infecti
diseas
replac
increas
incid
chronic
disord
exampl
diabet
ms
autism
asthma
allergi
caus
chronic
diseas
often
unknown
tempor
relationship
onset
childhood
vaccin
consider
specul
regard
causal
link
recent
studi
involv
children
born
denmark
show
support
causal
relationship
childhood
vaccin
diabet
consist
previou
studi
found
associ
type
diabet
recommend
childhood
vaccin
usa
possibl
relationship
hepat
b
vaccin
ms
also
rais
investig
result
two
largescal
studi
establish
signific
associ
hepat
b
vaccin
ms
moreov
evid
routin
vaccin
includ
hepat
b
increas
risk
exacerb
ms
inde
accumul
data
establish
hepat
b
vaccin
purifi
recombin
protein
among
safest
vaccin
develop
date
wraith
et
al
recent
review
evid
vaccin
could
caus
autoimmun
ddt
vol
octob
review
research
focu
diseas
conclud
autoimmun
featur
healthi
immun
system
occasion
trigger
infect
although
possibl
similar
phenomena
might
also
trigger
vaccin
littl
evid
suggest
result
autoimmun
diseas
fortun
immun
system
numer
failsaf
mechan
natur
reestablish
normal
balanc
adequ
respons
versu
respons
anaphylaxi
seriou
potenti
fatal
hypersensit
reaction
lead
varieti
distress
symptom
often
children
common
caus
anaphylaxi
includ
food
type
eg
peanut
medic
eg
penicillin
bee
sting
although
problem
caus
exposur
rang
materi
everyday
life
vaccineassoci
anaphylaxi
also
report
howev
anaphylaxi
rare
occurr
administr
vaccin
dose
five
potenti
case
vaccineassoci
anaphylaxi
report
give
risk
case
per
million
dose
none
result
death
addit
antigen
vaccin
contain
sever
compon
includ
preserv
adjuv
manufactur
residu
although
alway
clear
compon
might
respons
anaphylaxi
gelatin
egg
protein
present
vaccin
suffici
level
induc
hypersensit
reaction
vaccin
sourc
materi
suscept
individu
like
encount
agent
point
live
even
vaccin
exposur
physician
offic
reaction
treat
prefer
uncontrol
situat
exposur
could
occur
elsewher
level
mercuri
aluminium
formaldehyd
albumin
antibiot
yeast
protein
present
vaccin
shown
harm
human
experiment
anim
remov
thiomers
thimeros
mercurycontain
preserv
childhood
vaccin
recommend
american
academi
pediatr
http
wwwcdcgovnipvacsafeconcernsthimeros
recommend
remov
thiomers
caus
signific
problem
heighten
public
fear
children
alreadi
damag
use
vaccin
contain
compon
howev
evid
indic
low
level
mercuri
contain
vaccin
could
caus
harm
effect
http
wwwwhoint
vaccinesafetytopicsthiomersalen
subsequ
studi
confirm
ethylmercuri
thiomers
elimin
infant
rapidli
concentr
reach
blood
vaccin
well
level
associ
toxic
effect
unfortun
public
issu
result
percept
vaccin
contain
mercuri
unsaf
children
consequ
children
high
risk
develop
seriou
complic
influenza
infect
receiv
vaccin
adjuv
ad
vaccin
improv
immunogen
first
introduc
combin
tetanu
diphtheria
toxoid
vaccin
adjuv
licens
use
usa
insolubl
aluminium
salt
gener
call
alum
phosphat
hydroxid
salt
although
safeti
vaccin
adsorb
alum
establish
year
use
question
still
ask
concern
safeti
studi
shown
time
point
vaccin
calcul
bodi
burden
aluminium
remain
minim
risk
level
recent
metaanalysi
avail
safeti
data
alum
could
find
evid
seriou
longlast
advers
effect
alumadsorb
vaccin
induc
local
reaction
eg
red
pain
harden
inject
site
signific
number
recipi
usual
light
moder
short
durat
system
reaction
also
occasion
occur
includ
malais
fever
ach
although
alumadsorb
vaccin
link
previous
unknown
inflammatori
muscl
disord
call
macrophag
myofasc
evid
support
associ
minor
local
lesion
system
diseas
http
wwwwhoint
vaccinesafetytopicsaluminiumen
alum
favor
induct
thelper
cell
th
type
immun
respons
includ
immunoglobulin
e
antibodi
respons
suggest
alum
could
contribut
develop
allerg
reaction
predispos
individu
evid
support
recent
studi
use
birth
cohort
uk
investig
possibl
vaccin
could
respons
increas
preval
allergi
children
articl
conclud
routin
vaccin
risk
factor
asthma
eczema
highest
profil
vaccin
controversi
recent
year
unsubstanti
link
measl
mump
rubella
mmr
vaccin
autism
uk
wakefield
et
al
suggest
measl
vaccin
possibl
contributori
factor
develop
autism
predispos
children
media
storm
creat
uk
usa
hypothesi
led
drop
number
children
immun
therefor
enabl
measl
infect
recircul
advers
consequ
nonimmun
children
journal
publish
articl
wakefield
et
al
conjunct
major
author
report
print
partial
retract
paper
larg
possibl
associ
measl
autism
significantli
overinterpret
incid
becom
salutari
lesson
import
ensur
scientif
inform
convey
public
appropri
manner
preclud
interpret
support
fact
global
scale
measl
caus
death
peopl
mostli
children
howev
number
death
declin
drop
broader
use
mmr
vaccin
conjectur
mani
vaccin
administ
simultan
concomit
administr
multipl
vaccin
result
immun
system
overload
evid
support
propos
infant
enorm
capac
respond
safe
effect
multipl
vaccin
exampl
wholecel
pertussi
vaccin
alon
contain
mani
antigen
current
administ
children
routin
vaccin
recent
review
articl
directli
address
concern
parent
possibl
multipl
vaccin
weaken
immun
system
infant
conclud
evid
support
success
childhood
vaccin
partial
blame
hygien
hypothesi
suggest
infant
contract
infect
earli
life
immun
system
tilt
respons
toward
gener
atop
diseas
later
life
includ
allergi
asthma
thu
even
vaccin
accept
use
effect
still
highlight
potenti
caus
longterm
problem
howev
vaccin
prevent
mani
infect
contract
children
thu
even
fulli
vaccin
children
still
infect
pathogen
impact
develop
immun
system
evid
establish
tuberculosi
tb
vaccin
mycobacterium
bovi
bacillu
bcg
might
result
protect
effect
develop
allergi
probabl
wholecel
vaccin
induc
potent
respons
might
affect
respons
vaccin
administ
similar
time
howev
bcg
vaccin
longer
routin
develop
world
sever
recent
exampl
demonstr
impact
vaccin
reduc
mortal
morbid
introduct
proteinpolysaccharid
conjug
vaccin
neisseria
meningitidi
serogroup
c
uk
show
clear
reduct
number
death
figur
recent
introduct
pneumococcu
conjug
vaccin
similar
outcom
achiev
introduct
first
conjug
vaccin
hemophilu
influenza
type
b
hib
econom
impact
univers
vaccin
hib
recent
review
substanti
cost
benefit
highlight
vaccin
safe
well
toler
occurr
advers
event
rariti
henc
safeti
vaccin
need
consid
light
impact
reduc
death
diseas
addit
posit
impact
vaccin
also
incid
advers
consequ
result
failur
vaccin
sometim
consequ
percept
public
problem
vaccin
safeti
includ
measl
hepat
b
also
result
chang
vaccin
polici
routin
vaccin
japanes
schoolchildren
influenza
mandatori
law
relax
repeal
result
consider
drop
level
vaccin
subsequ
studi
show
chang
polici
signific
advers
effect
elderli
popul
japan
result
increas
number
death
chang
polici
larg
caus
sensation
report
lawsuit
alleg
advers
effect
ddt
vol
unsubstanti
result
public
lose
confid
vaccin
experi
japan
enabl
clear
correl
made
vaccin
polici
establish
herd
immun
posit
impact
vaccin
prevent
death
disabl
suscept
popul
sever
approach
develop
recent
potenti
produc
safer
vaccin
use
genom
inform
avail
import
microorgan
approach
term
revers
vaccinolog
enabl
identif
novel
recombin
antigen
potenti
excel
vaccin
candid
base
experi
recombin
hepat
b
vaccin
expect
highli
purifi
recombin
antigen
prove
much
safer
tradit
vaccin
sever
novel
vaccin
adjuv
improv
alum
current
undergo
clinic
preclin
test
includ
deliveri
system
design
promot
uptak
antigen
key
cell
immun
system
potent
immunopotenti
design
higher
specif
activ
cell
signific
barrier
develop
new
adjuv
requir
safeti
emulsionbas
adjuv
introduc
onto
european
market
addit
approach
expect
follow
come
year
advanc
understand
mechan
adjuv
work
alreadi
result
develop
safer
candid
specif
effect
limit
cell
type
trend
continu
improv
genet
engin
approach
includ
approach
revers
genet
enabl
product
viral
vector
predetermin
genet
defect
improv
safeti
addit
develop
nonrepl
viral
vector
eg
alphavirus
result
improv
safeti
tradit
approach
present
biggest
problem
vaccin
safeti
worldwid
inappropri
reus
needl
develop
countri
result
infect
bloodborn
pathogen
hiv
hepat
c
viru
hcv
howev
import
develop
use
autodispos
syring
needlefre
vaccinedeliveri
system
minim
problem
overal
increas
use
postlicensur
safeti
studi
often
call
phase
iv
studi
new
vaccin
product
ensur
safeti
issu
aris
even
low
level
identifi
quickli
alreadi
demonstr
oral
rotaviru
vaccin
iv
protect
threat
bioterror
furthermor
increas
awar
infecti
agent
often
caus
chronic
diseas
mani
might
prevent
even
treat
novel
vaccin
eg
hepat
b
c
therapeut
vaccin
would
abl
sustain
higher
level
advers
event
tradit
vaccin
particularli
use
oncolog
set
treat
life
threaten
infecti
diseas
would
use
peopl
alreadi
sick
infect
henc
benefittorisk
ratio
would
significantli
shift
favor
vaccin
level
scrutini
relat
safeti
would
chang
rappuoli
et
al
highlight
intang
valu
vaccin
immeasur
benefit
us
free
impact
sever
childhood
diseas
might
otherwis
led
prematur
death
result
irrepar
physic
mental
damag
howev
societi
current
valu
prevent
high
valu
therapi
unfortun
econom
valu
vaccin
undervalu
compar
pharmaceut
drug
result
mani
compani
choos
invest
vaccin
uk
govern
recent
express
concern
small
number
compani
produc
vaccin
signifi
suppli
vaccin
danger
econom
disincent
invest
vaccin
heighten
risk
liabil
live
increasingli
litigi
societi
lawyer
eager
take
case
individu
believ
neg
affect
medic
procedur
includ
vaccin
although
claim
complet
safeti
imposs
irrespons
medic
product
benefit
vaccin
far
outweigh
risk
public
need
educ
ensur
vaccin
recogn
mean
individu
establish
societi
respons
citizen
promot
use
vaccin
encourag
activ
particip
attempt
understand
neg
percept
vaccin
must
made
although
vast
major
peopl
receiv
benefit
vaccin
peopl
silent
contrast
suffer
advers
event
percept
advers
event
might
becom
passion
vocifer
oppon
vaccin
peopl
voic
opinion
overal
percept
vaccin
could
harm
good
although
medic
commun
gener
success
convinc
peopl
benefit
childhood
vaccin
educ
popul
benefit
vaccin
later
life
must
improv
come
year
avail
vaccin
target
adolesc
elderli
individu
increas
us
vaccin
commun
role
play
educ
public
greater
appreci
valu
vaccin
ensur
live
lost
prematur
prevent
infecti
diseas
number
avail
vaccin
increas
consequ
grow
awar
chronic
diseas
caus
infecti
agent
overal
field
vaccinolog
evolv
consider
past
centuri
much
learn
although
sometim
unfortun
mistak
today
potenti
develop
highli
purifi
safe
vaccin
predominantli
base
recombin
protein
proteinpolysaccharid
conjug
vaccin
elimin
problem
previous
encount
wholecel
liveattenu
product
moreov
mechan
place
enabl
evalu
larg
number
peopl
directli
address
concern
potenti
vaccin
induc
diabet
autism
ms
among
other
hope
confid
vaccin
improv
safeti
reach
unpreced
level
irrat
fear
continu
allay
convinc
scientif
data
howev
key
enhanc
confid
vaccin
total
transpar
real
unsubstanti
issu
vaccin
safeti
